

GOLDCOIN HEALTH FOODS LIMITED
Reg. Office : A-16, 1st Floor, Vardan Tower, Pragatinagar,
Naranpura, Ahmedabad – 380 013
M.: 094267 68644
Email: goldcoinhealth@gmail.com
CIN: L15419GJ1989PLC012041



Date: 23rd January, 2026

To,
The Corporate Relation Department
Bombay Stock Exchange Limited
P. J. Tower, Dalal Street,
Fort,
Mumbai - 400 001.

Dear Sir / Madam,

Sub: Submission of Unaudited Financial Results for the Third Quarter ended on 31st December, 2025.
Ref: Code: 538542

In reference to captioned subject and pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Standalone Unaudited Financial Results for the Third Quarter and Nine Months ended on 31st December, 2025.

Please take note of the same and oblige.

For, GoldCoin Health Foods Limited

Devang P Shah
Managing Director
(DIN : 00633868)

Limited Review Report

To,

Board of Directors of Goldcoin Health Foods Limited

We have reviewed the accompanying statement of unaudited financial results of **Goldcoin Health Foods Limited** for the quarter ended 31st December, 2025 which are included in the accompanying "Statement of Unaudited Financial Result for Quarter ended December 31, 2025" together with relevant notes thereon. The statement has been prepared by company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The statement is the responsibility of the company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting (Ind AS 34), prescribed under section 133 of the companies act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the ICAI. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 23/01/2026

Place : Ahmedabad

For, VSSB & Associates
Chartered Accountants

Firm No. 121356W



(Vishves A. Shah)

Partner

M. No. 109944

UDIN: 26109944SSLQQF9678



GOLDCOIN HEALTH FOODS LIMITED

(CIN : L15419GJ1989PLC012041)

Reg. Office: A/16 1st Floor, Vardan Tower Pragatinagar, Naranpura Vistar, Ahmedabad, Gujarat, India, 380013

E-mail: goldcoinhealth@gmail.com

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON DECEMBER 31, 2025

(Rs. in lacs except Earning per share Details)

Sr No	Particulars	Quarter ended December 31, 2025	Quarter ended September 30, 2025	Quarter ended December 31, 2024	Nine Month ended December 31, 2025 (Year to date for Current Period)	Nine Month ended December 31, 2024 (Year to date for Previous Period)	For the year ended on March 31, 2025
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Revenue From Operations						
	(a) Revenue from Operations	2.44	2.14	1.72	6.49	4.64	6.51
	(b) Other Income	-	0.30	-	12.63	-	2.23
	Total Income (Net)	2.44	2.44	1.72	19.13	4.64	8.74
2	Expenses						
	a. Cost of Materials Consumed	-	-	-	-	-	-
	b. Purchases of Stock-in-trade	2.01	1.82	1.46	5.52	3.96	5.52
	c. Changes in inventories of Stock-in-Trade	-	-	-	-	-	-
	d. Employee benefits expenses	2.25	2.60	2.95	7.10	7.45	10.05
	e. Finance Cost	0.24	0.23	0.09	0.58	0.35	0.41
	f. Depreciation and Amortization Expenses	0.01	0.01	0.50	0.04	1.50	0.06
	g. Other Expenses	3.98	0.21	(0.60)	9.28	4.80	4.91
	Total Expenses	8.50	4.87	4.39	22.52	18.06	20.95
3	Profit/(Loss) before Exceptional and Extraordinary items and tax (1-2)	(6.06)	(2.44)	(2.68)	(3.40)	(13.42)	(12.21)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before Extraordinary items and tax (3-4)	(6.06)	(2.44)	(2.68)	(3.40)	(13.42)	(12.21)
6	Extraordinary Items	-	-	-	-	-	-
7	Profit Before Tax (5-6)	(6.06)	(2.44)	(2.68)	(3.40)	(13.42)	(12.21)
8	Tax Expenses						
	(a) Current Tax	-	(1.60)	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	-
	Total Tax Expenses	-	(1.60)	-	-	-	-
9	Net Profit/(Loss) for the period from continuing Operations (7-8)	(6.06)	(0.83)	(2.68)	(3.40)	(13.42)	(12.21)
10	Profit (Loss) from Discontinuing operations before Tax	-	-	-	-	-	-
11	Tax Expenses of Discontinuing Operations	-	-	-	-	-	-
12	Net Profit/(Loss) from Discontinuing operations after Tax (10-11)	-	-	-	-	-	-
13	Share of Profit (Loss) of associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
14	Net Profit (Loss) for the period (9+12+13)	(6.06)	(0.83)	(2.68)	(3.40)	(13.42)	(12.21)
15	Other comprehensive income, net of income tax						
	a) i) Amount of item that will not be reclassified to profit or loss	-	-	-	-	-	-
	ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b) i) item that will be reclassified to profit or loss	-	-	-	-	-	-
	ii) income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income, net of income tax	-	-	-	-	-	-
16	Total Comprehensive income for the period	(6.06)	(0.83)	(2.68)	(3.40)	(13.42)	(12.21)
17	Details of equity share capital						
	Paid-up Equity Share Capital	150.05	300.09	300.09	150.05	300.09	300.09
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
18	Details of debt securities						
	Paid -Up Debt capital	-	-	-	-	-	-
	Face value of debt Securities	-	-	-	-	-	-
19	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	-	-	-	-	-	(198.32)
20	Debenture Redemption reserve	-	-	-	-	-	-
21	Earning per Share (See Note 4 below)						
i	Earning per Share for Continuing Operations						
	Basic Earning (Loss) per share from Continuing operations	(0.40)	(0.06)	(0.18)	(0.23)	(0.89)	(0.81)
	Diluted Earning (Loss) per share from Continuing operations	(0.40)	(0.06)	(0.18)	(0.23)	(0.89)	(0.81)
ii	Earning per Share for discontinuing Operations						
	Basic Earning (Loss) per share from discontinuing operations	-	-	-	-	-	-
	Diluted Earning (Loss) per share from discontinuing operations	-	-	-	-	-	-
iii	Earnings per Equity Share						
	Basic Earning (Loss) per share from Continuing and discontinuing operations	(0.40)	(0.06)	(0.18)	(0.23)	(0.89)	(0.81)
	Diluted Earning (Loss) per share from Continuing and discontinuing operations	(0.40)	(0.06)	(0.18)	(0.23)	(0.89)	(0.81)



Note:

1	The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 23rd January, 2026 .
2	The previous periods figures have been regrouped wherever necessary.
3	The company has passed special resolution in EGM (Extra Ordinary General Meeting) held as on 27/03/2025 for Approval of Reduction Of Share Capital. Company has received Approval Order regarding said scheme of Reduction of Share Capital from National Company Law Tribunal (NCLT) as on 31/10/2025.
4	<p>During the quarter, the Company implemented a scheme of reduction of share capital followed by consolidation of equity shares, whereby equity shares of face value ₹5 each were consolidated into equity shares of face value ₹10 each, effective 11 December 2025.</p> <p>In accordance with Ind AS 33, such consolidation is considered equivalent to a bonus issue for EPS computation purposes. Accordingly, the weighted average number of equity shares has been adjusted retrospectively, and EPS figures for all prior periods presented have been restated as if the consolidated equity shares had been outstanding for those periods.</p> <p>The Company does not have any potential equity shares; hence, Basic EPS and Diluted EPS are the same.</p>
5	The Statutory auditors of the company have carried out a "Limited Review report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Place: Ahmedabad
Date: 23/01/2026

For and on Behalf of the Board of
Goldcoin Health Foods Limited




Devang P Shah
(Managing Director)
(DIN - 00633868)